FDA Approved: ZYMFENTRA — Supplemental Application (CELLTRION USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ZYMFENTRA (infliximab-dyyb) submitted by Celltrion USA Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Zymfentra (Infliximab-dyyb)

Snippet

SUPPL AP for ZYMFENTRA (INFLIXIMAB-DYYB)